JOHNSON & JOHNSON COVID-19 VACCINE SHOWS STRONG IMMUNE RESPONSE IN EARLY TRIALS

Highlights

• The report published on Friday said that the safety profile and immunogenicity after only a single dose are supportive for further clinical development of vaccine named Arey.COV2.S at a dose level of 5x1010 vp, as a potentially protective vaccine against the COVID-19

• The report stated that a single dose of Arey.COV2.S elicited strong humoral responses in the vast majority of vaccine recipients.